Other · developed by iBio
IBIO-610 is an agent given by subcutaneous injection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07890870 | Phase 1 | Obesity & Overweight | Not yet recruiting | IBIO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Obesity & Overweight
Updated Nov 8, 2026. Something wrong or missing? Report it on the IBIO page.
See IBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IBIO catalysts and pipeline →